CN115068384A - Rapid whitening composition and application thereof - Google Patents
Rapid whitening composition and application thereof Download PDFInfo
- Publication number
- CN115068384A CN115068384A CN202210799036.5A CN202210799036A CN115068384A CN 115068384 A CN115068384 A CN 115068384A CN 202210799036 A CN202210799036 A CN 202210799036A CN 115068384 A CN115068384 A CN 115068384A
- Authority
- CN
- China
- Prior art keywords
- parts
- whitening composition
- whitening
- cosmetic
- quick
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002087 whitening effect Effects 0.000 title claims abstract description 94
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 239000002537 cosmetic Substances 0.000 claims abstract description 49
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 17
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims abstract description 17
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 claims abstract description 14
- 101710200814 Melanotropin alpha Proteins 0.000 claims abstract description 14
- 239000002562 thickening agent Substances 0.000 claims abstract description 13
- 239000005557 antagonist Substances 0.000 claims abstract description 11
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims abstract description 11
- 229940044601 receptor agonist Drugs 0.000 claims abstract description 10
- 239000000018 receptor agonist Substances 0.000 claims abstract description 10
- 239000003906 humectant Substances 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004902 Softening Agent Substances 0.000 claims abstract description 4
- 239000003755 preservative agent Substances 0.000 claims abstract description 4
- 230000002335 preservative effect Effects 0.000 claims abstract description 4
- 108010016731 PPAR gamma Proteins 0.000 claims abstract description 3
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims abstract 3
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims abstract 2
- 239000002131 composite material Substances 0.000 claims description 14
- 239000011259 mixed solution Substances 0.000 claims description 12
- 239000000284 extract Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- RTBWWWVNZWFNBV-SFHVURJKSA-N (2s)-3-phenyl-2-(undec-10-enoylamino)propanoic acid Chemical compound C=CCCCCCCCCC(=O)N[C@H](C(=O)O)CC1=CC=CC=C1 RTBWWWVNZWFNBV-SFHVURJKSA-N 0.000 claims description 7
- 239000003974 emollient agent Substances 0.000 claims description 7
- SBLKVIQSIHEQOF-UPHRSURJSA-N Octadec-9-ene-1,18-dioic-acid Chemical compound OC(=O)CCCCCCC\C=C/CCCCCCCC(O)=O SBLKVIQSIHEQOF-UPHRSURJSA-N 0.000 claims description 6
- 229940116224 behenate Drugs 0.000 claims description 6
- UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 229940116918 octadecenedioic acid Drugs 0.000 claims description 6
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims description 5
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- ULQISTXYYBZJSJ-UHFFFAOYSA-N 12-hydroxyoctadecanoic acid Chemical compound CCCCCCC(O)CCCCCCCCCCC(O)=O ULQISTXYYBZJSJ-UHFFFAOYSA-N 0.000 claims description 2
- KIHBGTRZFAVZRV-UHFFFAOYSA-N 2-Hydroxyoctadecanoic acid Natural products CCCCCCCCCCCCCCCCC(O)C(O)=O KIHBGTRZFAVZRV-UHFFFAOYSA-N 0.000 claims description 2
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 2
- 244000294611 Punica granatum Species 0.000 claims description 2
- 235000014360 Punica granatum Nutrition 0.000 claims description 2
- 240000000513 Santalum album Species 0.000 claims description 2
- 235000008632 Santalum album Nutrition 0.000 claims description 2
- OEWBEINAQKIQLZ-CMRBMDBWSA-N [(2s)-2-[(2r)-3,4-bis(2-hexyldecanoyloxy)-5-oxo-2h-furan-2-yl]-2-(2-hexyldecanoyloxy)ethyl] 2-hexyldecanoate Chemical compound CCCCCCCCC(CCCCCC)C(=O)OC[C@H](OC(=O)C(CCCCCC)CCCCCCCC)[C@H]1OC(=O)C(OC(=O)C(CCCCCC)CCCCCCCC)=C1OC(=O)C(CCCCCC)CCCCCCCC OEWBEINAQKIQLZ-CMRBMDBWSA-N 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N benzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 claims description 2
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims 1
- 241000222666 Boerhavia diffusa Species 0.000 claims 1
- 229940085633 glyceryl linolenate Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- GGJRAQULURVTAJ-PDBXOOCHSA-N rac-1-alpha-linolenoylglycerol Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(=O)OCC(O)CO GGJRAQULURVTAJ-PDBXOOCHSA-N 0.000 claims 1
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 abstract description 48
- 230000000694 effects Effects 0.000 abstract description 21
- 239000004480 active ingredient Substances 0.000 abstract description 20
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 8
- 210000002752 melanocyte Anatomy 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 230000001105 regulatory effect Effects 0.000 abstract description 5
- 201000004624 Dermatitis Diseases 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000000638 stimulation Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 19
- 102000023984 PPAR alpha Human genes 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 239000000839 emulsion Substances 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 230000002195 synergetic effect Effects 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 108060008724 Tyrosinase Proteins 0.000 description 4
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000008271 cosmetic emulsion Substances 0.000 description 4
- 230000001804 emulsifying effect Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108091006084 receptor activators Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101001134060 Homo sapiens Melanocyte-stimulating hormone receptor Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 102100034216 Melanocyte-stimulating hormone receptor Human genes 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 102000003425 Tyrosinase Human genes 0.000 description 3
- 102000013814 Wnt Human genes 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 230000003061 melanogenesis Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 231100000430 skin reaction Toxicity 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 229960000401 tranexamic acid Drugs 0.000 description 3
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 2
- 108010087806 Carnosine Proteins 0.000 description 2
- 206010008570 Chloasma Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000009795 Microphthalmos Diseases 0.000 description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 2
- PDHAOJSHSJQANO-OWOJBTEDSA-N Oxyresveratrol Chemical compound OC1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 PDHAOJSHSJQANO-OWOJBTEDSA-N 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000005282 brightening Methods 0.000 description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 2
- 229940044199 carnosine Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000005562 fading Methods 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 210000001061 forehead Anatomy 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 201000010478 microphthalmia Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 125000005629 sialic acid group Chemical group 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 1
- CSHZYWUPJWVTMQ-UHFFFAOYSA-N 4-n-Butylresorcinol Chemical compound CCCCC1=CC=C(O)C=C1O CSHZYWUPJWVTMQ-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 1
- 102000054930 Agouti-Related Human genes 0.000 description 1
- 241001313857 Bletilla striata Species 0.000 description 1
- 241001517299 Bulbophyllum Species 0.000 description 1
- XMWRBQBLMFGWIX-UHFFFAOYSA-N C60 fullerene Chemical compound C12=C3C(C4=C56)=C7C8=C5C5=C9C%10=C6C6=C4C1=C1C4=C6C6=C%10C%10=C9C9=C%11C5=C8C5=C8C7=C3C3=C7C2=C1C1=C2C4=C6C4=C%10C6=C9C9=C%11C5=C5C8=C3C3=C7C1=C1C2=C4C6=C2C9=C5C3=C12 XMWRBQBLMFGWIX-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- KFFCKOBAHMGTMW-LGQRSHAYSA-N Forsythin Chemical compound C1=C(OC)C(OC)=CC=C1[C@H]1[C@@H](CO[C@@H]2C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)[C@@H]2CO1 KFFCKOBAHMGTMW-LGQRSHAYSA-N 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 241000023813 Isia Species 0.000 description 1
- 102100031413 L-dopachrome tautomerase Human genes 0.000 description 1
- 101710093778 L-dopachrome tautomerase Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000916441 Lilium maritimum Species 0.000 description 1
- 101000680845 Luffa aegyptiaca Ribosome-inactivating protein luffin P1 Proteins 0.000 description 1
- 101150004219 MCR1 gene Proteins 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- ATGQXSBKTQANOH-UWVGARPKSA-N N-oleoylphytosphingosine Chemical compound CCCCCCCCCCCCCC[C@@H](O)[C@@H](O)[C@H](CO)NC(=O)CCCCCCC\C=C/CCCCCCCC ATGQXSBKTQANOH-UWVGARPKSA-N 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 108010015181 PPAR delta Proteins 0.000 description 1
- 102000000536 PPAR gamma Human genes 0.000 description 1
- 108010044210 PPAR-beta Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- JJVGFDTWFVSBIM-UHFFFAOYSA-N Phillyrin Natural products COc1ccc(cc1OC)C2OCC3C2COC3c4ccc(OC)c(OC5OC(CO)C(O)C(O)C5O)c4 JJVGFDTWFVSBIM-UHFFFAOYSA-N 0.000 description 1
- 244000302661 Phyllostachys pubescens Species 0.000 description 1
- 235000003570 Phyllostachys pubescens Nutrition 0.000 description 1
- 244000215777 Plumeria rubra Species 0.000 description 1
- 235000013087 Plumeria rubra Nutrition 0.000 description 1
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 101100206347 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pmh1 gene Proteins 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- 101710173693 Short transient receptor potential channel 1 Proteins 0.000 description 1
- 101710173694 Short transient receptor potential channel 2 Proteins 0.000 description 1
- 244000261559 Smilax china Species 0.000 description 1
- 235000000485 Smilax china Nutrition 0.000 description 1
- 240000009022 Smilax rotundifolia Species 0.000 description 1
- 235000003205 Smilax rotundifolia Nutrition 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- LVTKHGUGBGNBPL-UHFFFAOYSA-N Trp-P-1 Chemical compound N1C2=CC=CC=C2C2=C1C(C)=C(N)N=C2C LVTKHGUGBGNBPL-UHFFFAOYSA-N 0.000 description 1
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 1
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 1
- 244000178289 Verbascum thapsus Species 0.000 description 1
- 235000010599 Verbascum thapsus Nutrition 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000036566 epidermal hyperplasia Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229910003472 fullerene Inorganic materials 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008169 grapeseed oil Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940049918 linoleate Drugs 0.000 description 1
- 229940040452 linolenate Drugs 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-M linolenate Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC([O-])=O DTOSIQBPPRVQHS-PDBXOOCHSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229940084038 salix alba bark extract Drugs 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- YRWWOAFMPXPHEJ-OFBPEYICSA-K sodium L-ascorbic acid 2-phosphate Chemical compound [Na+].[Na+].[Na+].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1[O-] YRWWOAFMPXPHEJ-OFBPEYICSA-K 0.000 description 1
- 229940048058 sodium ascorbyl phosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/362—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
- A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pain & Pain Management (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a quick whitening composition and application thereof, and relates to the technical field of cosmetics. The invention provides a quick whitening composition, which comprises the following components: the PPAR-alpha receptor agonist is 0.01 to 1 part by weight, the PPAR-gamma receptor agonist is 0.5 to 4 parts by weight and the alpha-MSH antagonist is 0.3 to 5 parts by weight; the quick whitening composition is applied to preparing cosmetics, and the cosmetics comprise the following components: 0.81-10 parts of quick whitening composition, 0.6 part of thickening agent, 7.5 parts of humectant, 4 parts of emulsifier, 16 parts of softening agent, 1 part of preservative and 60.9-69.85 parts of water; the cosmetic containing the rapid whitening composition fully considers the transdermal absorption rate and the action target of the active ingredients, is more particularly selected and matched with the active ingredients capable of regulating the melanocyte extracellular target, so that the rapid whitening effect is realized, and meanwhile, the cosmetic is composed of a plurality of active ingredients aiming at melanin extracellular inhibition, has a strong anti-inflammatory effect, does not cause stimulation while rapidly whitening, and has the effect of relieving skin inflammation.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a quick whitening composition and application thereof.
Background
The problem of pigmentation, including post-inflammatory pigmentation, solar lentigo and chloasma, occurs widely in the human population, and thus there are many studies on this. Most products in the market achieve the effect of 'synergistic whitening' by adding various whitening components and interfering the formation of black in multiple directions or accelerating the catabolism of the black, but products designed in multiple directions, multiple targets and multiple paths may cause the action points of active components to be too dispersed so as not to achieve the effect of rapid whitening.
In order to protect the stem cells from the damage of ultraviolet rays, melanin generated by melanocytes is not distributed uniformly in the whole horny layer as expected, but most melanin is gathered in basal stem cells, and the melanin is covered on the cell nucleus as a black umbrellas to protect DNA from the invasion of ultraviolet rays. Although stem cells divide new keratinocytes, melanin is not evenly distributed to the daughter cells, and more melanin remains selectively in the basal layer. The existing conventional whitening products are more focused on selecting active ingredients for inhibiting the generation and the activity of the tyrosine enzyme, and the active ingredients related to the melanin synthase (such as tyrosinase, TRP-1 and TRP-2) inhibitor need to penetrate through an epidermal layer (a horny layer, a granular layer, a spinous layer and a basal layer) and then penetrate through a melanin cell membrane when reaching an action target point, so that the selection and the collocation are more focused on regulating and controlling the extracellular target point of the melanin cell in consideration of the transdermal absorption rate and the action target point of the active ingredients, thereby realizing the effect of rapid whitening, and becoming higher pursuits of people.
Chinese patent document CN111743851A discloses a whitening and spot-lightening composition and application thereof in 10/9/2020, wherein the whitening and spot-lightening composition comprises the following raw materials: yolk oil, shea butter, pterostilbene, vitamin E, hydrolyzed ceramide III, orange peel extract, yeast extract, thyme extract, white willow bark extract, mullein extract, lilium maritimum nerve activity whitening factors, scutellaria baicalensis extract, oxyresveratrol, lactobacillus fermentation lysate, tranexamic acid, VC ethyl ether, water-soluble fullerene, 4-butyl resorcinol and ectoin, and the whitening and spot-fading effects are remarkable by composing the whitening active ingredients to inhibit the activities of saccharifying enzyme and tyrosinase by two ways; chinese patent document CN114099652A discloses an acne-removing whitening preparation at 3 months and 1 days in 2022, and a preparation method and application thereof, wherein the acne-removing whitening preparation comprises the following raw materials in parts by weight: 4-6 parts of clove, 3-10 parts of leech, 12-18 parts of salvia miltiorrhiza, 10-15 parts of bletilla striata, 2-6 parts of chinaroot greenbrier rhizome, 6-8 parts of carboxymethyl chitosan, 1-3 parts of frangipani extract, 1-5 parts of phyllostachys pubescens extract, 1-1.5 parts of octadecenedioic acid, 2-3 parts of sodium ascorbyl phosphate, 10-15 parts of papain, 3-4 parts of phillyrin and 10-12 parts of grape seed oil, and the whitening cream is prepared by reasonable use and collocation of various components and a special process, has a remarkable synergistic effect, can efficiently inhibit the formation of melanin, achieves the whitening effect, and has various outstanding effects of moistening skin, sterilizing and diminishing inflammation and the like; chinese patent document CN114099365A discloses a nano composition of sialic acid for whitening and brightening skin and a preparation method and application thereof in 3.1.2022.A nano composition of sialic acid for whitening and brightening skin is prepared by jointly encapsulating active ingredients of different whitening mechanisms, namely sialic acid, undecylenoyl phenylalanine, carnosine, glutathione, tranexamic acid and salicylic acid, in the nano composition according to a melanin formation principle, so as to achieve the effect of synergistically increasing the whitening effect, wherein the sialic acid, the undecylenoyl phenylalanine, the carnosine and the glutathione have a synergistic effect and play a role in blocking the generation of melanin; the tranexamic acid is used as a protease inhibitor and plays a role in blocking melanin transport; the salicylic acid plays a role in accelerating cuticle shedding and melanin metabolism, so that the stability, the solubility and the whitening effect of the active ingredients are effectively improved; however, the whitening compositions in the prior art achieve the effect of rapid whitening by inhibiting the formation of melanin and blocking the transport of melanin, and the transdermal absorption rate and the action target of active ingredients are not considered, so that the selection and the collocation of the active ingredients are more focused on the regulation and control of the extracellular target of melanocytes, and the composition has great significance.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a quick whitening composition and application thereof, wherein the quick whitening composition is composed of a plurality of active ingredients aiming at melanin extracellular inhibition, the transdermal absorption rate of the active ingredients is improved, the selection and the collocation are more focused on the regulation and control ingredients capable of playing a role in melanocyte extracellular target spot, the quick whitening composition has a strong anti-inflammatory effect, and the quick whitening composition does not cause stimulation and has the effect of quickly relieving skin inflammation.
The invention provides a quick whitening composition, which comprises the following components: the PPAR-alpha receptor agonist is 0.01-1 part by weight, the PPAR-gamma receptor agonist is 0.5-4 parts by weight and the alpha-MSH antagonist is 0.3-5 parts by weight.
Further, the PPAR-alpha agonist is one or more of pterostilbene, sandalwood extract, hydroxystearic acid, glycerol linoleate and glycerol linolenate.
Further, the PPAR-gamma agonist is one or more of octadecenedioic acid and Bulbophyllum fulvellum root extract.
Further, the alpha-MSH antagonist is one or more of undecylenoyl phenylalanine, pomegranate seed extract, and ascorbyl tetraisopalmitate.
Further, the quick whitening composition comprises the following components: 0.5 part of pterostilbene, 2.5 parts of octadecenedioic acid and 2 parts of undecylenoyl phenylalanine in parts by weight.
The invention also provides a cosmetic containing the rapid whitening composition, which comprises the following components: the whitening composition comprises, by weight, 0.81-10 parts of a quick whitening composition, 0.6 part of a thickening agent, 7.5 parts of a humectant, 4 parts of a compound emulsifier, 16 parts of a softening agent, 1 part of a preservative and 60.9-69.85 parts of water.
Further, the thickening agent is formed by mixing xanthan gum and polyacrylate cross-linked polymer-6 according to the mass ratio of 1: 5.
Further, the composite emulsifier is prepared by mixing polyglycerol-6 stearate, glycerol stearate, cetostearyl alcohol and polyglycerol-6 behenate according to the mass ratio of 3:1:1: 3.
Further, the emollient is one or more of glyceryl tri (ethyl hexanoate), C12-15 alcohol benzoate, dimethicone, and coco-caprylate/caprate.
Further, the humectant is one or more of glycerin, pentanediol and diglycerin.
Further, the preservative is one or more of p-hydroxyacetophenone and 1, 2-hexanediol.
The invention also provides a preparation method of the cosmetic containing the quick whitening composition, which comprises the following steps:
s1, accurately weighing the raw material components according to the proportion;
s2, stirring and dissolving the thickening agent, the humectant and the water, and heating to 80-85 ℃ to obtain a mixed solution;
s3, premixing the composite emulsifier, the emollient and the whitening composition, adding the premixed composite emulsifier, the emollient and the whitening composition into the mixed solution, homogenizing and stirring the mixed solution uniformly, and cooling the mixed solution to 50 ℃;
s4, adding antiseptic, stirring and dissolving to uniformity to obtain the cosmetic.
In addition, it is also worth noting the rapid whitening mechanism of the present invention, which is specifically described as follows:
microphthalmia transcription related factor (MITF) is a key regulation factor in a melanin synthesis path of an animal body, influences the development and differentiation of melanocytes by regulating the expression quantity of TYR genes in tissues of the animal body so as to regulate the melanin generation quantity, is a target gene of a plurality of signal paths for melanin synthesis, and is a core link for the melanin synthesis. Pigmentation control involves multiple signaling pathways, the most common ones that regulate melanogenesis are the cAMP-dependent, Wnt and ERK signaling pathways, all of which involve MITF; the most prominent of the three pathways is the α -MSH/MC1R pathway, α -MSH (α -melanocyte-stimulating hormone) is derived from pro-melanocortin POMC, is produced and released by keratinocytes, and binds to melanocyte melanocortin receptor 1(MC1R), and MC1R, upon activation, increases the signaling cascade that stimulates melanogenesis through MITF. The invention inhibits the melanogenesis process of each step initiated by alpha-MSH by adding an alpha-MSH melanogenesis-promoting inhibitory antagonist, namely an alpha-MSH antagonist, stimulates an 'AGRP' type protein, plays a determining role in controlling and binding an MCR1 receptor, and thus realizes the regulation and control of MITF; the undecylenoyl phenylalanine is an alpha-MSH antagonist, can play a role in biochemical reactions of various stages of melanin formation initiated by alpha-MSH, intercepts melanin generation signals, controls the combination of the alpha-MSH and melanin generation factors, inhibits the activity of the enzyme tyrosine, further inhibits the formation of the melanin, and prevents the synthesis of the melanin from the source; PPARs belong to a subfamily of nuclear hormone receptors, involving three distinct subtypes of PPARs, known as PPAR α, PPAR β/δ, and PPAR γ; PPARs and their corresponding ligands are potential targets for the treatment of various skin disorders, including abnormal keratinocyte differentiation, epidermal hyperplasia, inflammation and defective permeability barrier function, in which- α and- γ receptors are expressed in human melanocytes and activators thereof may act to inhibit melanocyte growth; the invention regulates epidermal lipid synthesis and metabolism by adding PPAR-alpha receptor agonist, in the skin, PPAR-alpha activation is proved to be capable of regulating permeability barrier homeostasis, epidermal differentiation, lipid biosynthesis and inflammatory genes, and the invention can significantly increase proteins related to WNT pathway by providing activated PPAR-alpha, thereby realizing the regulation of MITF; the peroxisome proliferator-activated receptor (PPAR-gamma) activator is the strongest subtype influencing cell proliferation and pigmentation, the activated PPAR-gamma inhibits Wnt/beta-chain protein channel by inducing the degradation of beta-chain protein protease, and further realizes the regulation and control of MITF, wherein octadecenedioic acid is added to regulate the expression of tyrosinase gene, inhibit the generation of tyrosinase, and further reduce the generation of melanin. In summary, the present invention preferably selects an active ingredient capable of regulating the expression of microphthalmia transcription factor (MITF) to achieve the effect of rapid whitening by selecting an alpha-MSH antagonist, a PPAR-alpha receptor activator or a PPAR-gamma receptor activator.
In addition, the active ingredients in the cosmetic containing the quick whitening composition provided by the invention comprise an alpha-MSH antagonist, a PPAR-alpha receptor activator and a PPAR-gamma receptor activator, and the phenomena of water-oil incompatibility, unstable and nonuniform emulsion system are easy to occur, and the inventor finds that the problem can be well solved by adding a composite emulsifier formed by mixing polyglycerol-6 stearate, glycerol stearate, cetostearyl alcohol and polyglycerol-6 behenate according to the mass ratio of 3:1:1:3, and the reason may be that: the polyglycerol-6 stearate and polyglycerol-6 behenate polyglycerol ester are used as co-emulsifiers, have wider hydrophilic-lipophilic balance value, strong emulsifying capacity, good hydrolysis resistance, strong emulsifying property, strong thermal stability and strong viscosity reduction; cetostearyl alcohol has effects of inhibiting greasy feeling, and stabilizing cosmetic emulsion; the glyceryl stearate has good hydrolysis resistance and strong emulsifying capacity, and the polyglycerol-6 stearate, the glyceryl stearate, the cetearyl alcohol and the polyglycerol-6 behenate are mixed to form a composite emulsion according to the mass ratio of 3:1:1:3, and the composite emulsion has a synergistic effect, has better hydrophilic capacity, can reduce the surface tension of water, forms micelles, and changes the size and range of colloid interaction between droplets, so that the cosmetic emulsion has better compatibility of active substances, more stable emulsion system, more favorable skin permeation of emulsified particles, and more remarkable effects of rapid whitening and removing red and inflammation.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention considers the transdermal absorption rate and the action target of the active ingredients, and the selection and the collocation are more focused on the regulation and control ingredients capable of playing the role of the extracellular target of the melanocyte, thereby realizing the effect of rapid whitening;
2. the quick whitening composition disclosed by the invention is composed of three active ingredients aiming at melanin extracellular inhibition, namely a PPAR-alpha receptor agonist, a PPAR-gamma receptor agonist and an alpha-MSH antagonist, has a synergistic effect, can achieve a higher and faster whitening effect, does not cause stimulation while quickly whitening, and has the effect of quickly relieving skin inflammation;
3. the whitening composition containing the cosmetics is compounded by multiple components through scientific formula, the quick whitening composition is matched with components such as a softening agent, a humectant, a composite emulsifier, a thickening agent and the like to form an emulsion, so that the emulsion forms a stable emulsifying system, the formed emulsion is mild, has good compatibility with skin and has lower irritation to the skin and eyes, the components are mutually coordinated, the whitening and freckle-removing components of the composition can better act on the skin, and the emulsion has better whitening and red-removing anti-inflammatory effects; the composite emulsifier is prepared by mixing polyglycerol-6 stearate, glyceryl stearate, cetearyl alcohol and polyglycerol-6 behenate according to the mass ratio of 3:1:1:3, the thickening agent is prepared by mixing xanthan gum and polyacrylate cross-linked polymer-6 according to the mass ratio of 1:5, and the composite emulsifier has a good stability effect on a cosmetic emulsion system containing the quick whitening composition, so that emulsified particles are more beneficial to skin permeation, and the effects of quick whitening, red removal and anti-inflammation are more remarkable.
Drawings
FIG. 1 is a VISIA local standard light map and brown speckle map of subject 1 among 2 randomly selected subjects in test example III;
FIG. 2 is a VISIA local standard light map and brown speckle map of subject 2 among 2 subjects randomly selected in test example III;
FIG. 3 is a VISIA red area chart of 1 volunteer No. 1 randomly selected from group 1 taken within 2 days in test example four.
Detailed Description
Experimental procedures according to the invention, in which no particular conditions are specified in the following examples, are generally carried out under conventional conditions, or under conditions recommended by the manufacturer. The various chemicals used in the examples are commercially available.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The terms "comprising" and "having," and any variations thereof, are intended to cover non-exclusive inclusions. For example, a process, method, apparatus, article, or apparatus that comprises a list of steps is not limited to only those steps or modules recited, but may alternatively include other steps not recited, or may alternatively include other steps inherent to such process, method, article, or apparatus.
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the description is intended to be exemplary only, and is not intended to limit the scope of the present invention. Moreover, in the following description, descriptions of well-known structures and techniques are omitted so as to not unnecessarily obscure the concepts of the present invention.
The invention is further described in the following examples, which are not intended to limit the scope of the invention.
Preparation of cosmetics of examples 1 to 3 and comparative examples 1 to 5
Specific formulations of examples of cosmetics containing the quick whitening composition are shown in table 1, and comparative examples 1 to 5 are different from example 1 only in the formulation of the cosmetics, and the specific formulations are shown in table 1.
Tables 1, examples 1 to 3 and comparative examples 1 to 5 formulation tables (parts by weight)
Compared with example 3, comparative examples 1 to 3 are the same in the same parts and materials as the rapid whitening composition with the changed components; compared with the example 3, the comparative example 4 has the advantages that the component proportion of the composite emulsifier is changed, and the rest materials and parts are the same; compared with example 3, comparative example 5 shows that the component ratio of the thickener is changed, and the rest materials and parts are the same.
The preparation steps of the cosmetics of examples 1 to 3 and comparative examples 1 to 5 are the same, specifically:
s1, accurately weighing the raw material components according to the proportion;
s2, stirring and dissolving the thickening agent, the humectant and water, and heating to 80-85 ℃ to obtain a mixed solution;
s3, premixing the composite emulsifier, the emollient and the quick whitening composition, adding the premixed mixture into the mixed solution, homogenizing and stirring the mixed solution uniformly, and cooling the mixed solution to 50 ℃;
s4, adding antiseptic, stirring and dissolving to uniformity to obtain the cosmetic.
Test example one, whitening self-evaluation test
(1) Test samples: the cosmetics prepared in examples 1 to 3 and comparative examples 1 to 5;
(2) the test method comprises the following steps: selecting 17-50 years old subjects with chloasma and dark complexion, half of each male and female, 56 persons in total, dividing into 7 groups, 8 subjects in each group, randomly dividing the subjects, and respectively trying the samples of examples 1-3 and comparative examples 1-5 on the face (one sample is used in each group); the dosage is 0.2 g/time, 2 times/day (1 time in the morning and evening), the effect is judged by self after one month, and the judgment standard is divided into three degrees: significantly whitened, slightly whitened, unchanged or deteriorated;
(3) and (3) test results:
TABLE 2 whitening self-evaluation test results
| Marked whitening | Slightly whitened | Without change or deterioration | |
| Example 1 | 4 | 3 | 1 |
| Example 2 | 3 | 4 | 1 |
| Example 3 | 7 | 1 | 0 |
| Comparative example 1 | 2 | 3 | 3 |
| Comparative example 2 | 1 | 4 | 3 |
| Comparative example 3 | 2 | 4 | 2 |
| Comparative example 4 | 1 | 3 | 4 |
| Comparative example 5 | 1 | 4 | 3 |
As can be seen from the results in table 2, the whitening cosmetics prepared in examples 1 to 3 of the present invention all had good whitening effects after being applied to the facial skin, wherein the whitening effect of example 3 is the most significant and is the best example of the present invention; the cosmetics prepared in the comparative examples 1 to 3 have a reduced whitening effect due to the lack of any component in the quick whitening composition, which indicates that the rapid whitening composition provided by the invention has a synergistic whitening effect due to the compounding of various active ingredients; the components in the emulsifier in the cosmetic prepared in the comparative example 4 are not compounded according to the mass ratio of 3:1:1:3, so that the whitening active ingredients in the prepared cosmetic cannot be well compounded and compatible, and the whitening effect on skin is not obvious; the cosmetic prepared in the comparative example 5 has low stability of the cosmetic emulsion system, the effect of the active substance is reduced, and the whitening effect of the prepared cosmetic is also reduced because the components in the thickener are not compounded according to the mass ratio of 1: 5.
Test example two, Mild efficacy test
(1) Test samples: the cosmetics prepared in examples 1 to 3;
(2) the test basis is as follows: testing the skin patch of a human body according to the safety technical specification 2015 edition of cosmetics;
(3) negative control: control wells are blank (no material placed);
(4) test prescriptionThe method comprises the following steps: selecting 96 individuals of test subjects by adopting a 24-hour closed patch test, dividing the test subjects into 3 groups, wherein each group comprises 32 individuals, each group comprises 25 women and 7 men, the age is 18-59 years, the cosmetic prepared in the embodiment 1-3 is respectively used according to the volunteer selection standard of the test subjects, and then the cosmetic with the area not more than 50mm is selected 2 A suitable spot tester with a depth of about 1mm, wherein 0.2g of each of the cosmetics prepared in examples 1 to 3 is added into the spot tester by a closed spot test method, the spot tester is applied to the curved side of the forearm of a subject, the forearm is lightly pressed with a palm to be uniformly applied to the skin, the subject is removed after 24 hours, the skin reaction is observed at 0.5 hour, 24 hours and 48 hours after the removal, and the result is recorded according to the skin reaction grading standard of the skin closed spot test in the technical Specification for cosmetic safety 2015;
TABLE 3 skin response grading Standard for skin Enclosed Patch test
(5) And (3) test results:
TABLE 4 Mild test results
As can be seen from the data in Table 3, the results of the human skin patch test of the cosmetics prepared in examples 1 to 3 of the present invention are all negative, indicating that the cosmetics prepared in examples 1 to 3 of the present invention are mild and have no irritation to the skin.
Test example three, whitening efficacy test
(1) Test samples: the cosmetic prepared in example 3;
(2) the test method comprises the following steps: screening 10 volunteers with obvious skin color and color, selecting the face as a test part, wherein the test period is 28 days, and observing the face condition of the volunteers 1 day before and 14 and 28 days after the sample is used; 1 week prior to the test is the elution period during which the subjects used a base moisturizing lotion and a moisturizing milk without any actives, during which no other whitening products could be used; the subjects used the cosmetic samples prepared in example 1 for 28 consecutive days, applied the samples to the face every day in the morning and at night before sleeping, and then applied the amount of about 0.2g, and evaluated by the 5-stage method: obviously improve-slightly improve-invariable-slightly worsen-obviously worsen, record the number of people of each number condition, randomly choose VISIA local standard light chart and brown spot chart of 2 subjects to evaluate the change condition of facial pigment before and after use;
(3) and (3) test results:
TABLE 5 whitening efficacy test results
As can be seen from the data in table 5, in the subjects who used the whitening cosmetics prepared in example 3, the number of facial pigments significantly improved was 8, and the whitening effect was significant; 2 randomly selected subjects, as can be seen from figure 1, subject No. 1, after using the cosmetic sample for 14 days (i.e. two weeks), the whole face is obviously brightened, the redness of the face subsides, the dark skin also obviously whitens, and from the brown speckle pattern, the degree of pigment deposition in the deep layer of the skin is obviously reduced, and the dark of the whole face subsides; as can be seen from the attached figure 2, the whole skin color of the subject 2 becomes white when the return visit is performed for two weeks, the return visits for four weeks are continuously improved, dark red cheeks disappear and the forehead part becomes white obviously through the analysis of a standard light chart, and the color depth of the forehead part can be obviously lightened through the brown spot chart of the subject 2, which shows that the cosmetic containing the quick whitening composition prepared by the invention has a remarkable quick whitening effect.
Test example four test of anti-inflammatory efficacy of anti-redness
(1) Test samples: the cosmetics prepared in example 3 and comparative examples 1 to 5;
(2) the test method comprises the following steps: screening 60 volunteers having red blood streak on their cheeks, dividing them into 6 groups of 10 persons, using the cosmetics prepared in example 3 and comparative examples 1 to 5, respectively; selecting a face as a test part, wherein the test period is 14 days, and observing the face red blood streak regression condition of the volunteers 1 day before and 14 days after the sample is used; 1 week prior to the test is the elution period during which the subjects used basal moisturizing water and moisturizing milk without any actives, and no other products were used during the test period; the cosmetic samples were applied to 6 groups of subjects for 14 consecutive days, and the samples were applied to the face in an amount of about 0.2g per day after washing the face before sleeping in the morning and at night, and evaluated by the 5-stage method: significant improvement-slight improvement-unchanged-slight deterioration-significant deterioration, the number of relevant persons was recorded; then randomly drawing 1 volunteer No. 1 of the group 1, shooting the face with ISIA CR every day, and evaluating the change condition of the red blood streak on the face before and after use by using a VISIA red area diagram;
(3) and (3) test results:
TABLE 6 Deerythroid anti-inflammatory efficacy test results
As can be seen from the results in the above table, the facial blood streak of 10 volunteers using the cosmetic prepared in example 3 of the present invention was significantly improved, which indicates that the cosmetic containing the rapid whitening composition prepared in the present invention has significant anti-inflammatory and anti-redness efficacy; as can be seen from the randomly extracted VISIA red area diagram of volunteer No. 1 referring to fig. 3, after the whitening cosmetic prepared in embodiment 3 of the present invention is used, the significant fading of red blood streak on the cheek and the significant lightening of the whole red area of the face can be seen in only 2 days, which indicates that the rapid whitening composition prepared in the present invention has not only rapid whitening effect, but also rapid red-removing anti-inflammatory effect; whereas comparative example 1 had no anti-erythro inflammatory efficacy due to the lack of PPAR-gamma receptor agonist; in comparative examples 2 to 5, the stability of the cosmetic system was deteriorated and the red-removing anti-inflammatory effect was remarkably decreased due to the change in the ratio of other active ingredients or the compound emulsifier to the thickener.
It should be noted that specific features, structures, materials or characteristics described in this specification may be combined at will, and for brevity of description, all possible combinations of features in the above embodiments may not be described, and those skilled in the art may combine and combine features of different embodiments and features of different embodiments described in this specification without contradiction.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. A quick whitening composition is characterized by comprising the following components: the pharmaceutical composition comprises, by weight, 0.01-1 part of PPAR-alpha receptor agonist, 0.5-4 parts of PPAR-gamma receptor agonist and 0.3-5 parts of alpha-MSH antagonist.
2. The rapid whitening composition according to claim 1, wherein the PPAR-alpha agonist is one or more of pterostilbene, Sandalwood extract, hydroxystearic acid, glyceryl linoleate and glyceryl linolenate.
3. The rapid whitening composition according to claim 1, wherein the PPAR-gamma agonist is one or more of octadecenedioic acid and Boerhavia diffusa root extract.
4. The quick whitening composition according to claim 1, wherein the alpha-MSH antagonist is one or more of undecylenoyl phenylalanine, pomegranate seed extract and ascorbyl tetraisopalmitate.
5. The quick whitening composition according to claim 1, comprising the following components: 0.5 part of pterostilbene, 2.5 parts of octadecenedioic acid and 2 parts of undecylenoyl phenylalanine in parts by weight.
6. A cosmetic comprising the quick whitening composition according to any one of claims 1 to 5, characterized by comprising the following components: the whitening composition comprises, by weight, 0.81-10 parts of a quick whitening composition, 0.6 part of a thickening agent, 7.5 parts of a humectant, 4 parts of a compound emulsifier, 16 parts of a softening agent, 1 part of a preservative and 60.9-69.85 parts of water.
7. The cosmetic according to claim 6, wherein the thickener is a mixture of xanthan gum and polyacrylate crosspolymer-6 in a mass ratio of 1: 5.
8. The cosmetic according to claim 6, wherein the composite emulsifier is prepared by mixing polyglycerol-6 stearate, glycerol stearate, cetostearyl alcohol and polyglycerol-6 behenate according to a mass ratio of 3:1:1: 3.
9. The cosmetic of claim 6, wherein the emollient is one or more of glyceryl tri (ethyl hexanoate), C12-15 alcohol benzoate, dimethicone, and coco-caprylate/caprate.
10. A method for preparing a cosmetic product according to any one of claims 6 to 9, comprising the steps of:
s1, accurately weighing the raw material components according to the proportion;
s2, stirring and dissolving the thickening agent, the humectant and the water, and heating to 80-85 ℃ to obtain a mixed solution;
s3, premixing the composite emulsifier, the emollient and the whitening composition, adding the premixed composite emulsifier, the emollient and the whitening composition into the mixed solution, homogenizing and stirring the mixed solution uniformly, and cooling the mixed solution to 50 ℃;
s4, adding antiseptic, stirring and dissolving to uniformity to obtain the cosmetic.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210799036.5A CN115068384A (en) | 2022-07-08 | 2022-07-08 | Rapid whitening composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210799036.5A CN115068384A (en) | 2022-07-08 | 2022-07-08 | Rapid whitening composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115068384A true CN115068384A (en) | 2022-09-20 |
Family
ID=83257899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210799036.5A Pending CN115068384A (en) | 2022-07-08 | 2022-07-08 | Rapid whitening composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115068384A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115778880A (en) * | 2023-02-01 | 2023-03-14 | 卡莱丽化妆品有限公司 | Liposome, preparation method and application thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1566168A1 (en) * | 2004-02-23 | 2005-08-24 | Laboratoires S.V.R. | Dermo-cosmetic compositions for depigmenting and use of it |
| US20070185038A1 (en) * | 2005-09-30 | 2007-08-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin care actives |
| US20100189795A1 (en) * | 2009-01-16 | 2010-07-29 | Neocutis S.A. | Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions |
| US20110158922A1 (en) * | 2008-04-15 | 2011-06-30 | Immanence Integrale Dermo Correction Inc. | Skin Care Compositions and Method of Use Thereof |
| US20160243015A1 (en) * | 2013-10-25 | 2016-08-25 | Conopco, Inc., D/B/A Unilever | Skin lightening composition |
| US20200306172A1 (en) * | 2017-02-06 | 2020-10-01 | Nunii Laboratoire | Depigmenting dermatological and cosmetic compositions |
| CN111743785A (en) * | 2019-03-28 | 2020-10-09 | 珀莱雅化妆品股份有限公司 | Nanofiber membrane with whitening and tightening effects and preparation method thereof |
| WO2021138031A1 (en) * | 2019-12-30 | 2021-07-08 | Rodan & Fields, Llc | Ppar agonist complex and methods of use |
-
2022
- 2022-07-08 CN CN202210799036.5A patent/CN115068384A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1566168A1 (en) * | 2004-02-23 | 2005-08-24 | Laboratoires S.V.R. | Dermo-cosmetic compositions for depigmenting and use of it |
| US20070185038A1 (en) * | 2005-09-30 | 2007-08-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin care actives |
| US20110158922A1 (en) * | 2008-04-15 | 2011-06-30 | Immanence Integrale Dermo Correction Inc. | Skin Care Compositions and Method of Use Thereof |
| US20100189795A1 (en) * | 2009-01-16 | 2010-07-29 | Neocutis S.A. | Calcium sequestration compositions and methods of treating skin pigmentation disorders and conditions |
| US20160243015A1 (en) * | 2013-10-25 | 2016-08-25 | Conopco, Inc., D/B/A Unilever | Skin lightening composition |
| US20200306172A1 (en) * | 2017-02-06 | 2020-10-01 | Nunii Laboratoire | Depigmenting dermatological and cosmetic compositions |
| CN111743785A (en) * | 2019-03-28 | 2020-10-09 | 珀莱雅化妆品股份有限公司 | Nanofiber membrane with whitening and tightening effects and preparation method thereof |
| WO2021138031A1 (en) * | 2019-12-30 | 2021-07-08 | Rodan & Fields, Llc | Ppar agonist complex and methods of use |
Non-Patent Citations (2)
| Title |
|---|
| JOSIE MARAN 公司: ""Smoothing Hand Treatment"", pages 1 - 5, Retrieved from the Internet <URL:http://www.gnpd.com/sinatra/recordpage/8725535/?utm_source=download&utm_medium=rtf> * |
| 彭冠杰，郭清泉: "《美白化妆品科学与技术》", 中国轻工业出版社, pages: 186 - 188 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115778880A (en) * | 2023-02-01 | 2023-03-14 | 卡莱丽化妆品有限公司 | Liposome, preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021017846A1 (en) | Enhanced anti-aging cosmetic composition | |
| WO2018196482A1 (en) | Skin care cosmetic composition | |
| CN110721104B (en) | Whitening cream and preparation method thereof | |
| WO2021031750A1 (en) | Mixed birch sap and application thereof in skin care cosmetic composition | |
| CN110664685B (en) | Essence emulsion for improving anti-glycation effect of skin and preparation method thereof | |
| US11911498B2 (en) | Low pH skin care composition and methods of using the same | |
| KR102067009B1 (en) | Inhibitor for NO activator, Anit-inflammation agent containing of the same, Revitalizing cosmetics containing the same and Manufacturing method thereof | |
| TW200904482A (en) | Compositions and methods for inhibiting melanogenesis | |
| CN112587456B (en) | Repairing and whitening composition and preparation method thereof | |
| CN103142435A (en) | Whitening composition inhibiting tyrosinase activities with multiple mechanisms, and products of composition | |
| CN110339078A (en) | It is a kind of to have effects that nourish the composition of maintenance skin and its application | |
| CN115400065A (en) | Skin care composition with multiple effects of moisturizing, resisting wrinkles, resisting aging, relieving and repairing and application thereof | |
| EP3102181B1 (en) | Active complex for a skin anti-ageing cosmetic | |
| CN115068384A (en) | Rapid whitening composition and application thereof | |
| EP1262169B1 (en) | Skin anti-ageing composition | |
| CN115154383A (en) | Mild whitening composition and whitening cream thereof | |
| CN116763702A (en) | Composition for fading deep spots as well as preparation method and application thereof | |
| JP2009298752A (en) | Skin care preparation composition for external use | |
| JP5858654B2 (en) | White hair prevention / treatment agent, non-therapeutic beauty method, endothelin receptor B gene expression promoter and MITF-M gene expression promoter | |
| CN115737451A (en) | Alpha-gel composition, cosmetic and preparation method thereof | |
| JP5010582B2 (en) | Depigmenting or glossy cosmetic composition comprising at least one oxazoline as an active ingredient | |
| CN115463048A (en) | Acne-removing face-refreshing essence and preparation method thereof | |
| US20070286915A1 (en) | Nerve Growth Factor Production Inhibitor and External Preparation for the Skin, Cosmetic, Quasi Drug, Preventive and Remedy for Atopic Dermatitis Containing the Nerve Growth Factor Production Inhibitor | |
| CN114344202A (en) | Anti-aging composition, skin care product and cosmetic | |
| US20160089319A1 (en) | Actives for stimulating differentiation of keratinocytes to lighten hyperpigmented skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220920 |